Predicting lymphoma development in patients with Sjögren's syndrome

Area of Science:

• Autoimmune diseases
• Oncology
• Rheumatology

Background:

• Primary Sjögren's syndrome (pSS) is an autoimmune disorder characterized by inflammation and lymphoproliferation in exocrine glands.
• Malignant transformation to lymphoma is a significant concern in pSS patients.
• Accurate prediction of lymphoma risk is essential for timely intervention and improved patient outcomes.

Purpose of the Study:

• To review and discuss the current predictors of lymphoma in primary Sjögren's syndrome.
• To highlight key clinical and biological factors associated with increased lymphoma risk.
• To emphasize the need for improved prediction strategies and ongoing research.

Main Methods:

• Review of established and emerging predictors for lymphoma in pSS.
• Focus on clinical manifestations such as persistent salivary gland swelling and cryoglobulinemic vasculitis.
• Inclusion of laboratory markers like low C4, serum cryoglobulinemia, lymphopenia, and rheumatoid factor (RF).

Main Results:

• Persistent salivary gland swelling and cryoglobulinemic vasculitis are major predictors of lymphoma in pSS.
• These predictors are linked to increased mucosa-associated lymphoid tissue (MALT) involvement and specific RF-positive clones.
• Other indicators include lymphadenopathy, splenomegaly, neutropenia, lymphopenia, and elevated beta2-microglobulin.

Conclusions:

• Current lymphoma prediction in pSS requires enhancement and repeated assessment during follow-up.
• Harmonization of large cohorts and development of new biomarkers are necessary.
• Future research directions include salivary gland echography and scoring MALT involvement for improved risk stratification.